A recent survey conducted by researchers from MIT, Harvard, and Monash University has highlighted growing concerns about the future of biomedical science in the United States. Initially designed to examine how biomedical labs are managed, the survey evolved into a broader investigation of how funding cuts and political directives from the White House are affecting early-career scientists.
The survey, released this summer as a working paper by the National Bureau of Economic Research, gathered responses from over 900 junior researchers across 134 institutions. Participants were asked to assess their likelihood of continuing in academia and remaining in the US, both at the time of the survey in March 2025 and six months prior. Results showed a marked decline in enthusiasm: those intending to stay in academia dropped from 66 percent to 44 percent, while those wanting to remain in the US decreased from approximately 93-95 percent to around 72 percent. Though the authors note possible recall bias and the fluid nature of intentions, they emphasize that these early-career scientists represent the future principal investigators and leaders of American research, raising concerns about long-term impacts on the scientific community.
The backdrop to these changing attitudes includes substantial grant funding cuts and freezes from the National Institutes of Health (NIH) and the National Science Foundation (NSF), some reportedly linked to the Trump administration’s scrutiny of diversity, equity, and inclusion (DEI) initiatives. Academics such as Raffaella Sadun from Harvard Business School point to the political environment as a significant factor prompting uncertainty among young researchers.
Further compounding unease is an anticipated executive order from the White House that would introduce a politically appointed board to evaluate NIH grant applications, aiming to eliminate what critics label as “woke” science. This move follows a rejected proposal by the White House Office of Management and Budget (OMB) to give political appointees greater reviewing authority within federal agencies. Opponents warn this approach risks politicizing the grant review process and could delay or terminate critical clinical trials and research projects.
Brady West, a University of Michigan research professor and statistician who has experienced grant terminations and reinstatements amid these changes, expressed concern that talented scientists may be withdrawing from federally funded research. He criticized the dismissive attitude toward what is being termed “woke” science, emphasizing that impactful research should be judged solely on its scientific merit and potential to benefit society.
Patient advocacy groups and scientific organizations have voiced similar warnings. Erika Sward, executive director of United for Cures, said the plan threatens timely medical breakthroughs and could erode American competitiveness in biotechnology. The American Association for the Advancement of Science cautioned that prioritizing political considerations over scientific quality risks overlooking groundbreaking research that often emerges unexpectedly.
The NIH, OMB, and Department of Health and Human Services have not provided comments on these developments. Meanwhile, critics cite additional concerns about the administration’s actions in health policy, including grant restrictions tied to keyword censorship, controversies surrounding childhood vaccination programs, mandated testosterone screenings in the military, and disputed claims relating to painkiller use during pregnancy.
As uncertainty mounts, many early-career scientists face a precarious environment, prompting some to reconsider their futures in US biomedical research. Observers warn that the cumulative effect of these political and funding pressures could significantly hinder American health innovation and leadership in the years to come.